RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Overview

This is an open-label, single-arm, non-randomized multicenter Phase 2 study evaluating RAPA-201 cells in subjects with relapsed, refractory multiple myeloma. After a subject consents to the study, an apheresis procedure will be performed to collect cells to manufacture the investigational product, RAPA-201 cells. During Cycle 1, subjects will receive pentostatin and low-dose, dose-adjusted Cyclophosphamide (PC regimen), but will not receive RAPA-201 cells. During Cycles 2 and beyond, Subjects will receive a conditioning regimen consisting of the PC regimen followed by the RAPA-201 cell infusions. Subjects will receive at minimum five cycles of treatment. If a subject has stable disease, they will receive an additional four cycles of PC regimen+RAPA-201 cells. All subjects who complete the active treatment portion of the study, prematurely terminate the study, or subjects who discontinue active treatment due to a toxicity attributable or related to the study drug will complete the follow-up portion of the study (approximately one year). Patients who experience progressive disease will be taken off study.

SparkCures ID 1053
Trial Phase Phase 2
Enrollment 27 Patients
Treatments
Trial Sponsors
  • Rapa Therapeutics LLC
Trial Collaborators
  • Medical College of Wisconsin
NCT Identifier

NCT04176380

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Male or female patients ≥ 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Diagnosis of relapsed, refractory multiple myeloma.
  • Exposure to at least three different prior lines of therapy including exposure to at least two proteosome inhibitors (e.g. bortezomib), and at least two immunomodulatory drugs (e.g. lenalidomide) and at least one anti-CD38 monoclonal antibody agent (e.g. daratumumab) Documentation of a prior line of therapy must include at least one of the following three items: [1] medical records detailing prior treatment, best response to treatment, and date of progression; [2] myeloma markers (SPEP, UPEP, Immunoglobulin, FLC) at time of treatment and progression; or, [3] documentation by investigator/treating physician to be included in patient's medical and research record (for example, note in electronic medical record), indicating prior treatment, best response to treatment, and data of progression. To qualify as a prior line of therapy, ≥ 2 cycles of therapy must be administered unless the disease is refractory, or the regimen is not tolerated.
  • Refractory status to ≥ one proteasome inhibitor AND ≥ one immunomodulatory drug. Refractory disease is defined as <25% reduction in M-protein/free light chain difference (involved vs. uninvolved) or disease progression during treatment or ≤ 60 days after treatment cessation. Patient may or may not be refractory to anti-CD38 therapy.
  • Presence of secretory myeloma/measurable disease, as defined by:
    1. Serum M-protein (SPEP) ≥ 0.5 mg/dL or
    2. Urine M-protein (UPEP) ≥ 200 mg/24 hours
    3. Light chain MM: Serum free light chain (FLC) assay ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa/lambda FLC ratio.
  • Must have a potential source of autologous T cells potentially sufficient to manufacture RAPA-201 cells, as defined by a circulating CD3+ T cell count ≥ 400 cells/µL.
  • Patients must be ≥ two weeks from last myeloma therapy, major surgery, radiation therapy and participation in investigational trials.
  • Patients must have recovered from clinical toxicities (resolution of CTCAE toxicity to a value of ≤ 2).
  • Ejection fraction (EF) by MUGA or 2-D echocardiogram within institution normal limits, with an EF level of ≥ 40%.
  • Serum creatinine ≤ to 2.5 mg/dL.
  • Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ to 3 x upper limit of normal (ULN).
  • Absolute neutrophil count (ANC) of ≥ 1000 cells/µL (independent of growth factor support for at least 7 days prior to screening).
  • Platelet count of ≥ 50,000 cells/µL, with value obtained (independent of growth factor support or transfusion support for at least 7 days prior to screening).
  • Hemoglobin count ≥ 8 grams/µL (independent of growth factor support or transfusion support for at least 7 days prior to screening).
  • Bilirubin ≤ 1.5 (except if due to Gilbert's disease).
  • Corrected DLCO ≥ 50% (Pulmonary Function Test).
  • No history of abnormal bleeding tendency.
  • Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.

Exclusion Criteria:

  • Prior allogeneic stem cell transplantation.
  • Current plasma cell leukemia (circulating myeloma > 20% of leukocytes).
  • Other active malignancy (except for non-melanoma skin cancer).
  • Non-secretory multiple myeloma (difficult to assess by IMWG criteria).
  • Evidence of systemic AL Amyloidosis involving any vital organ. Incidental histologic demonstration of amyloid deposition in marrow/within plasmacytoma is not considered organ involvement.
  • Life expectancy <4 months.
  • Patients seropositive for HIV, hepatitis B, or hepatitis C.
  • Uncontrolled hypertension.
  • History of cerebrovascular accident within 6 months of enrollment.
  • Myocardial infarction within 6 months prior to enrollment.
  • NYHA class III/IV congestive heart failure.
  • Uncontrolled angina/ischemic heart disease.
  • Subjects with known central nervous system disease.
  • Pregnant or breastfeeding patients.
  • Patients of childbearing age, or males who have a partner of childbearing potential, who are unwilling to practice contraception.
  • Patients may be excluded at PI discretion or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.
  • Subjects should not receive any prior systemic therapy within 14 days of the protocol required apheresis procedure.

US Trial Locations

Not Currently Accepting Patients

The following is a listing of trial locations that are not currently open and accepting patients.

Verified Medical College of Wisconsin Froedtert Hospital

SparkCures Verified Accurate, up-to-date information. Learn more

Wisconsin
Verified Medical College of Wisconsin Froedtert Hospital

SparkCures Verified Accurate, up-to-date information. Learn more

Resources

There are no resources, links or videos to display for this clinical trial.